Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U03 Substudy 03C in recurrent clear cell renal cell carcinoma after adjuvant anti-PD-(L)1 therapy
2024-516437-12-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of belzutifan and zanzalintinib in clear cell renal cell carcinoma (ccRCC), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities, Adverse events and 2 more. Planned start Aug 2025; status: authorised.
02
Drugs
belzutifanzanzalintinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-516437-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516437-12-00.